Immune response modifier compounds for treatment of TH2 mediated and related diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 21, 2000
Issued Date -
N/A
app pub date -
Oct 24, 1997
filing date -
Oct 25, 1996
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Immune response modifier compounds--imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines--are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully